Cerulean Pharma Inc. Presentation Selected as a Top Poster at the...

Among the findings, Cerulean will present clinical and pre-clinical efficacy data for CRLX101 as a combination therapy with anti-angiogenic therapies for renal cell carcinoma and ovarian cancer.

http://www.biospace.com/news_story.aspx?StoryID=312254&full=1